# Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure

> **NCT03750552** · PHASE3 · COMPLETED · sponsor: **Theravance Biopharma** · enrollment: 195 (actual)

## Conditions studied

- Symptomatic Neurogenic Orthostatic Hypotension

## Interventions

- **DRUG:** ampreloxetine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03750552
- **Lead sponsor:** Theravance Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-24
- **Primary completion:** 2021-07-21
- **Final completion:** 2021-07-21
- **Target enrollment:** 195 (ACTUAL)
- **Last updated:** 2022-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03750552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03750552, "Clinical Effect of Ampreloxetine (TD-9855) for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03750552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*